Quan Dong Nguyen, MD

New and different therapies emerging through uveitis pipelineLocal therapy plays a significant role in the treatment of uveitis, either as monotherapy or in combination therapy. Alongside a number of pharmacotherapeutic agents, new products and technologies are in development that could expand clinicians’ options and improve outcomes.
Positive results reported for anti-interleukin-6 agent for uveitisIntravenous administration of the anti-interleukin-6 (IL-6) agent tocilizumab (Actemra, Genentech) is well-tolerated in patients with non-infectious uveitis involving the posterior segment and showing promising efficacy, according to interim outcomes reported by Quan Dong Nguyen, MD.
iCo completes phase II iDEAL DME study enrollmentiCo Therapeutics Inc. announced it has completed enrollment of its phase II iDEAL Study, which will evaluate the efficacy and safety after repeated injections of iCo-007 in patients with diabetic macular edema (DME).